Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial

Introduction Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection of immunocompromised hosts with significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15–20 mg/kg/day, is associated with serious adverse drug events (A...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Benedetti, Cecilia T Costiniuk, Kosar Khwaja, Andrew Johnson, Barret Rush, Darrell Tan, Ranjani Somayaji, Salman Qureshi, Michaeline McGuinty, Nicole Ezer, Sara Belga, Emily G. McDonald, Zahra N. Sohani, Guillaume Butler-Laporte, Andrew Aw, Alex Carignan, Matthew P. Cheng, Bryan Coburn, Dan Gregson, Alexander Lawandi, Victor Leung, Sylvain Lother, Derek MacFadden, Leighanne Parkes, Valerie Roy, Ilan Schwartz, Miranda So, Emilie Trinh, Todd C. Lee
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/7/e053039.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/12/7/e053039.full

Similar Items